Bymetric
UK company intelligence
Company Active LTD

Company profile

Proteinlogic Limited

Protein Logic ProteinLogic has developed ImmiPrint, a novel diagnostic technology platform

Proteinlogic Limited is a UK company with status active founded in 2003 based in East of England.

CRN
04762891
Founded
2003
Age
23

Overview

Legal name
PROTEINLOGIC LIMITED
Region
East of England
Registered address
50/60 STATION ROAD
CAMBRIDGE
ENGLAND
CB1 2JH
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

27 May
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

13 May
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

25 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzE2NzI0MWFkaXF6a2N4

Published 25 Sep 2024 09:47

13 May
2003

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2012
Funded years
2012, 2013, 2014, 2015
Age at first award
9 years

Projects

2015 Feasibility Studies Lead participant

Technical and Commercial Feasibility of a blood test for prediction of response to interferon treatment in Chronic Hepatitis B patients

1 Jan 2015 to 31 Jul 2015

Awarded
£118,064
Total cost £157,419

Hepatitis B is the most common chronic viral disease in the world with over 350 million chronic carriers. Taking into account the recent migration patterns it is estimated that that there are now more than 300,000 people in the UK with HBV infection and, of these, 78,000 have Chronic Hepatitis B infection. NICE recommends that interferon be used as the fi...

2014 Collaborative R&D Lead participant

Research to create point-of-care TB diagnostic prototype from ProteinLogic unique TB biomarker signature and Microtest novel rapid diagnostic platform [MicroLogic].

1 Nov 2014 to 30 Apr 2015

Awarded
£405,055
Total cost £675,091

Tuberculosis (TB) is responsible for over four million deaths each year. Globally there were an estimated 8.9 million new cases during 2011 and it is also a concern in the UK where there are approximately nine thousand new cases each year. Early detection and treatment is important to prevent the disease from spreading. Current diagnostic tests either lac...

2013 Feasibility Studies Lead participant

Feasibility of rapid point-of-care diagnostic test for TB

1 Sep 2013 to 30 Nov 2013

Awarded
£10,270
Total cost £13,694

There were an estimated 8.8 million new cases of TB in 2010 and an estimated 1.4 million deaths, making this disease one of the world's biggest infectious killers. It is estimated that 1/3 of the global population is infected with latent disease. Disease transmission occurs primarily via droplets from coughing and sneezing. Early diagnosis and treatment o...

2013 Feasibility Studies Lead participant

Feasibility of developing a novel biomarker signature as an innovative diagnostic for tuberculosis (TB)

1 Mar 2013 to 31 Dec 2013

Awarded
£76,922
Total cost £102,652

There were an estimated 8.8 million new cases of TB in 2010 and an estimated 1.4 million deaths, making this disease one of the world's biggest infectious killers. It is estimated that 1/3 of the global population is infected with latent disease. Disease transmission occurs primarily via droplets from coughing and sneezing. Early diagnosis and treatment o...

2012 Special Interest Group Lead participant

Assessment of the market opportunity and unmet need for a hepatitis B diagnostic test which is predictive of response to treatment

1 Sep 2012 to 28 Feb 2013

Awarded
£63,662
Total cost £63,662

Awaiting Public Project Summary

Product types

Collaborative R&D Feasibility Studies Special Interest Group